[go: up one dir, main page]

PL373490A1 - Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases - Google Patents

Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases

Info

Publication number
PL373490A1
PL373490A1 PL02373490A PL37349002A PL373490A1 PL 373490 A1 PL373490 A1 PL 373490A1 PL 02373490 A PL02373490 A PL 02373490A PL 37349002 A PL37349002 A PL 37349002A PL 373490 A1 PL373490 A1 PL 373490A1
Authority
PL
Poland
Prior art keywords
beta
treatment
neurodegenerative diseases
adrenoceptor agonists
adrenoceptor
Prior art date
Application number
PL02373490A
Other languages
Polish (pl)
Inventor
Josef Krieglstein
Carsten Culmsee
Vera Junker
Helmut Blum
Wolfgang Greb
Original Assignee
Eucro European Contract Research Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10142175A external-priority patent/DE10142175A1/en
Priority claimed from DE10142178A external-priority patent/DE10142178A1/en
Priority claimed from DE10142176A external-priority patent/DE10142176A1/en
Priority claimed from DE10149611A external-priority patent/DE10149611A1/en
Application filed by Eucro European Contract Research Gmbh & Co.Kg filed Critical Eucro European Contract Research Gmbh & Co.Kg
Publication of PL373490A1 publication Critical patent/PL373490A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0619Neurons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Addiction (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
PL02373490A 2001-08-29 2002-08-22 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases PL373490A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10142175A DE10142175A1 (en) 2001-10-09 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142178A DE10142178A1 (en) 2001-08-29 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10142176A DE10142176A1 (en) 2001-08-29 2001-08-29 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases
DE10149611A DE10149611A1 (en) 2001-08-29 2001-10-09 Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
PL373490A1 true PL373490A1 (en) 2005-09-05

Family

ID=27438007

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02373490A PL373490A1 (en) 2001-08-29 2002-08-22 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases

Country Status (5)

Country Link
EP (1) EP1420772A2 (en)
JP (1) JP2005505548A (en)
AU (1) AU2002333510A1 (en)
PL (1) PL373490A1 (en)
WO (1) WO2003020257A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754474A1 (en) * 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Use of S-Clenbuterol
GB0519274D0 (en) * 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases
AU2007226134A1 (en) * 2006-03-16 2007-09-20 Mor Research Applications Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
CN101915841B (en) * 2010-07-26 2013-01-02 河南省科学院生物研究所有限责任公司 Ternary detection test bar of beta-stimulants albuterol, clenobuterol hydrochloride and ractopamine and preparation method thereof
US9265735B2 (en) 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor
CN115531368A (en) * 2021-06-14 2022-12-30 谭文 Application of R-carbamate-beta-phenylethanolamine compounds in treatment of learning and memory deficiency and neurodegenerative diseases
CN116236467B (en) * 2023-02-07 2023-10-27 中国人民解放军总医院 New application of simatron or derivative thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
EP0392059B1 (en) 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Use of adamantane derivatives in the prevention and treatment of cerebral ischemia
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
CA2411666A1 (en) * 2000-06-01 2001-12-06 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
US7135497B1 (en) * 2000-07-07 2006-11-14 New York Medical College Treating neural conditions resulting from spinal cord contusions and other causes

Also Published As

Publication number Publication date
AU2002333510A1 (en) 2003-03-18
JP2005505548A (en) 2005-02-24
WO2003020257A3 (en) 2004-01-08
WO2003020257A2 (en) 2003-03-13
EP1420772A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
ZA200401004B (en) Combination for the treatment of inflammatory disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
HUP0400024A3 (en) Combination for treatment of neoplastic diseases
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
PL373490A1 (en) Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
GB0119370D0 (en) Therapeutic agent
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
GB0123991D0 (en) New therapeutic use
GB0128122D0 (en) Therapeutic use
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
AU2002365654A8 (en) Treatment of diseases via the skin
GB0203173D0 (en) The treatment of neurodegenerative disease
GB0107114D0 (en) New therapeutic use
GB0112491D0 (en) New therapeutic use
GB0128304D0 (en) New therapeutic use
GB0110584D0 (en) New therapeutic use
GB0128300D0 (en) New therapeutic use
GB0119462D0 (en) New therapeutic use
GB0110585D0 (en) New therapeutic use
GB0128123D0 (en) Therapeutic use
GB0128089D0 (en) Therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)